Den dokumenterede indberetningsfrekvens for augmentation i forbindelse med dopaminagonister, herunder ropinirol, er generelt lavere end for levodopa.
The reported rates in the literature of augmentation associated with dopamine agonists including ropinirole are generally lower than the ones reported for levodopa.